Celltrion Group announced that the merger agreement between Celltrion, Inc. was approved at the extraordinary general meeting of shareholders (“EGM”) of the two companies held at Songdo Convensia and Sheraton Grand Incheon Hotel, respectively, on October 23, 2023.
Seegene's eco-friendly shipping box is composed of 12-paper layers, biodegradable films, recycled PET packaging, a vacuum insulation panel, dry ice, and ice packs. The materials are either 100% renewable or certified as "green" via organizations such as the Forest Stewardship Council (FSC) and the Ministry of Environment in Korea.
TriasMD, a musculoskeletal management company and parent of the DISC Surgery Centers, has announced its acquisition of Walnut Creek-based Pinnacle Surgery Center ("Pinnacle").
Pint Pharma and OrphanDC announced on July 25th that ANVISA, the National Health Surveillance Agency, approved, on July 25th, 2023, the drug EMPAVELI® (pegcetacoplan, indicated for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH)). Empaveli is the first treatment for PNH that binds to the complement protein C3.
A state-of-the-art, next-generation automated drug dispensing machine equipped with a robotic arm, independently developed by JVM, an affiliate of Hanmi Science, was successfully launched in the European market.
Alimentiv Inc. ("Alimentiv"), a leading Contract Research Organization focused on GI-related therapeutics, is pleased to announce the addition of new scientific advisors to its scientific advisory board.
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced the publication of two cases of long-term disease-free survival in the treatment of advanced hepatocellular carcinoma (HCC) with CARsgen's innovative CAR-GPC3 T-cell therapy.
Cambrex announced the completion of its $38 million capacity expansion at its small molecule active pharmaceutical ingredient (API) manufacturing facility in High Point, North Carolina.
Maryland-based biotech company Deka Biosciences ("Deka") announced that it has successfully closed a USD $20 Million Series B2 financing with a syndicate of life science investors led by MPM BioImpact, and joined by additional investors including Leaps by Bayer, Lumira Ventures, O-Bio (Echo Investment Capital), Viva BioInnovator, Alexandria Venture Investments, Amana Investments, Plains Ventures, ATEM Capital and CEO John Mumm.
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced that "LEQEMBI® Intravenous Infusion" (200 mg, 500mg, lecanemab) has been approved in Japan as a treatment for slowing progression of mild cognitive impairment (MCI) and mild dementia due to Alzheimer's disease (AD). The regulatory approval in Japan announced today, entitles BioArctic to a milestone of EUR 17 M.